Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors (GCT): A phase 1 study

被引：0
|
作者：
Albany, Costantine [1 ]
Hashemi, Neda S. [1 ]
Fang, Fang [2 ]
Lowder, James [3 ]
Einhorn, Lawrence [1 ]
Nephew, Kenneth [2 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] Indiana Univ, Bloomington, IN USA
[3] Astex Pharmaceut Inc, Pleasanton, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1386
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design
    Naqvi, Kiran
    Gonzalez, Garciela Nogueras
    Cheung, Cora
    Pemmaraju, Naveen
    Jabbour, Elias
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Ohanian, Maro
    Jain, Nitin
    Takahashi, Koichi
    Alvarado, Yesid
    Konopleva, Marina
    Huang, Xuelin
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S6
  • [42] Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT):: a phase II study
    Mardiak, J
    Sálek, T
    Sycová-Milá, Z
    Obertová, J
    Hlavatá, Z
    Mego, A
    Recková, M
    Koza, I
    NEOPLASMA, 2005, 52 (03) : 243 - 247
  • [43] THE ROLE OF IFOSFAMIDE PLUS CISPLATIN-BASED CHEMOTHERAPY AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY GERM-CELL TUMORS
    MOTZER, RJ
    COOPER, K
    GELLER, NL
    BAJORIN, DF
    DMITROVSKY, E
    HERR, H
    MORSE, M
    FAIR, W
    SOGANI, P
    RUSSO, P
    BOSL, GJ
    CANCER, 1990, 66 (12) : 2476 - 2481
  • [44] Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer
    Kollmannsberger, C
    Gerl, A
    Schleucher, N
    Beyer, J
    Kuczyk, M
    Rick, O
    Gasper, J
    Sosada, M
    Rie, C
    Kanz, L
    Bokemeyer, C
    ANTI-CANCER DRUGS, 2000, 11 (07) : 535 - 539
  • [45] Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
    Lassen, Ulrik
    Mau-Sorensen, Morten
    Buhl, Ulla Hald
    Madsen, Mogens W.
    Balslev, Eva
    Pluim, Dick
    Schellens, Jan H. M.
    Knudsen, Steen
    Jensen, Peter B.
    CANCER RESEARCH, 2016, 76
  • [46] Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT).
    Feldman, D. R.
    Patil, S.
    Trinos, M. J.
    Carousso, M.
    Ginsberg, M. S.
    Sheinfeld, J.
    Bajorin, D. F.
    Bosl, G. J.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study
    Chung, Woonbok
    Taverna, Pietro
    Lyons, John F.
    Hao, Yong
    Azab, Mohammad
    Kantarjian, Hagop M.
    Kropf, Patricia
    Issa, Jean-Pierre
    BLOOD, 2013, 122 (21)
  • [48] Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors:: a phase II study
    Mardiak, J
    Sálek, T
    Sycová-Milá, Z
    Obertová, J
    Hlavatá, Z
    Mego, M
    Recková, M
    Koza, I
    NEOPLASMA, 2005, 52 (06) : 497 - 501
  • [49] A PROSPECTIVE MULTICENTER GETUG PHASE II TRIAL OF GEMCITABINE, CISPLATIN, AND IFOSFAMIDE (GIP) IN PATIENTS WITH RELAPSED METASTATIC GERM-CELL TUMORS (GCT)
    Fizazi, K.
    Gravis, G.
    Flechon, A.
    Geoffrois, L.
    Chevreau, C.
    Laguerre, B.
    Delva, R.
    Eymard, J.
    Burcoveanu, D.
    Culine, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 271 - 272
  • [50] A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
    Adra, Nabil
    Vaughn, David J.
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    Funt, Samuel A.
    Rosales, Matt
    Arozullah, Ahsan
    Feldman, Darren R.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1087 - 1094
12345